Notice of Extraordinary General Meeting, proposed company dissolution and delisting

Core Viewpoint - PCI Biotech Holding ASA is proposing to dissolve the company and delist its shares from Euronext Oslo Børs due to the absence of operational activity and the expectation that such activity will not resume [2][3]. Group 1: Company Dissolution - The Board of Directors has proposed the resolution to dissolve PCI Biotech as there is no longer any operational activity within the company [2]. - The wholly owned subsidiary, PCI Biotech AS, has also resolved to initiate a parallel dissolution process [2]. Group 2: Delisting from Euronext Oslo Børs - The proposed resolution to delist the shares is based on the lack of operational activity and a limited asset base, leading the Board to conclude that the company is no longer suitable for public trading [3]. - The Board recommends that the delisting should occur as soon as possible [3].